Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
The Gabelli Healthcare & Wellness Trust is a closed-end fund (CEF) managed by Gabelli Funds that invests in healthcare and wellness-related equities, including pharmaceuticals, biotechnology, medical devices, managed care, and healthcare services companies. The fund trades at a discount to NAV (P/B of 0.9x) and generates income through dividends from portfolio holdings and option premium strategies, while seeking capital appreciation through active stock selection in the healthcare sector.
The fund generates returns through active portfolio management of healthcare equities, collecting dividends from underlying holdings, realizing capital gains from strategic buying/selling, and writing covered calls to generate premium income. Management fees are charged at approximately 1.0% of net assets annually. The fund employs leverage (D/E of 0.45) to amplify returns, borrowing at short-term rates to invest in higher-yielding healthcare equities. Pricing power comes from Gabelli's specialized healthcare research capabilities and the closed-end structure that allows patient capital deployment without redemption pressure.
Net Asset Value (NAV) performance driven by healthcare sector equity returns, particularly large-cap pharma and biotech holdings
Discount/premium to NAV fluctuations - currently trading at ~10% discount based on P/B of 0.9x
Distribution coverage and sustainability - ability to maintain dividend payments from portfolio income
Healthcare sector sentiment driven by drug pricing legislation, FDA approval cycles, and Medicare/Medicaid policy changes
Interest rate changes affecting both leverage costs (borrowing at short-term rates) and CEF valuation multiples
Healthcare regulatory risk including drug pricing reforms, Medicare negotiation expansion under IRA provisions, and potential single-payer healthcare proposals that could compress pharmaceutical and managed care margins
Closed-end fund structural discount persistence - CEFs historically trade at 5-15% discounts to NAV during normal markets, widening to 20%+ during stress periods, creating permanent capital impairment risk
Leverage refinancing risk - the fund's 45% leverage requires continuous access to short-term credit markets; disruptions could force deleveraging at unfavorable prices
Competition from lower-cost healthcare ETFs (XLV, VHT, IBB) offering similar exposure at 0.10-0.40% expense ratios versus GRX's ~1.0% management fee plus leverage costs
Open-end mutual fund alternatives (GGHCX, PRHSX) providing daily liquidity without discount-to-NAV risk
Passive index strategies capturing healthcare beta at fraction of active management costs, particularly challenging given the fund's modest 1.4% ROE
Leverage magnification risk - 45% debt-to-equity amplifies both gains and losses; a 20% portfolio decline becomes 27% NAV decline with leverage
Extremely low current ratio of 0.03 indicates minimal liquid assets relative to short-term obligations, creating potential forced selling risk during market dislocations
Distribution sustainability risk - with 15% net margin and 6.9% FCF yield, distributions may exceed sustainable earnings during weak market periods, requiring return of capital
moderate - Healthcare equities exhibit defensive characteristics during recessions (non-discretionary demand for pharmaceuticals and medical services), but biotech and elective procedure companies show cyclical sensitivity. The fund's diversified healthcare exposure provides some GDP insulation, though capital gains realization depends on market liquidity and investor risk appetite.
Rising rates negatively impact the fund through two channels: (1) increased borrowing costs on the 45% leveraged portfolio, directly reducing net investment income, and (2) CEF valuation compression as fixed-income alternatives become more attractive, widening discounts to NAV. A 100bp rate increase could reduce NII by 15-20% on the leveraged portion. Conversely, falling rates reduce financing costs and support CEF premium expansion.
Moderate - The fund's leverage (D/E 0.45) creates exposure to credit market conditions. Tightening credit spreads and stable short-term funding markets are essential for maintaining leverage at attractive costs. During credit stress, forced deleveraging could require selling portfolio holdings at inopportune times. The fund does not have direct credit exposure through loan portfolios.
dividend - The fund attracts income-focused investors seeking healthcare sector exposure with regular distributions (6.9% FCF yield). The closed-end structure and discount-to-NAV also appeal to value investors looking for asset-backed securities trading below intrinsic value. However, the modest 1.4% ROE and negative recent returns (-6.4% 1-year) suggest limited appeal to growth or momentum investors.
moderate-to-high - Closed-end funds exhibit elevated volatility versus underlying holdings due to discount/premium fluctuations and leverage amplification. The 45% leverage magnifies healthcare sector moves by ~1.45x. Recent performance shows -6.1% over 3 months, suggesting beta above 1.0. CEF-specific volatility from forced selling during redemptions and sentiment-driven discount widening adds to total volatility profile.
